Sunesis / Takeda Pharmaceutical Company Limited / Shanghai (hereinafter “Takeda (China) Holdings / Takeda China / Baxter International Inc. / Affymax Inc. / Zinfandel Pharmaceuticals Inc. / Fujisawa / Takeda Group / Dainippon Sumitomo Pharma Co. Ltd. / Intra-Cellular Therapies Inc. / Janssen Pharmaceutical K.K. / Seattle Genetics Inc. / Takeda Pharmaceuticals North America Inc. / Amgen Inc. / Takeda Pharmaceutical (China) Company Limited / Millennium Pharmaceuticals Inc. / Biogen Idec / Therapeutics Inc. / Orexigen / Takeda (China) Holdings Co. Ltd. / Fiscal 2010 (China) Holdings / Takeda Medicines India Private Limited / Tianjin Takeda Pharmaceuticals Co. Ltd / Tokyo Stock Exchange / /
Continent
Europe / Americas / Asia / /
Country
Switzerland / Norway / Japan / Brazil / Canada / Portugal / United Kingdom / China / India / Denmark / Mexico / Sweden / Belgium / Turkey / Russia / United States / Spain / South Korea / Ireland / /
Currency
USD / EUR / JPY / /
Event
FDA Phase / Dividend Issuance / Company Expansion / M&A / Business Partnership / Product Recall / Product Issues / Reorganization / Natural Disaster / /
Facility
Kyoto University / Sanford-Burnham Medical Research Institute / Hikari Plant / Florida Hospital / /
IndustryTerm
overall business strategies / manufacturing facility / individual products / treatment of prostate cancer / pharmaceutical industry / owned subsidiary / cell-based influenza vaccine technology / reimbursement systems / treatment of schizophrenia and bipolar disorder / treatment of anemia in chronic renal failure / hypertension treatment / manufacturing subsidiaries / manufacturing / diabetes treatment / cross-functional disease area management / technology transfer / treatment of advanced or recurrent colorectal cancer / treatment of insomnia / existent subsidiary / cancer treatment / healthcare / pharmaceutical / expert / sales network / pharmaceutical market / treatment of hypertension / research networking / treatment of obesity / /
MedicalCondition
recurrent ovarian cancer / multiple myeloma / chronic renal failure / rheumatoid arthritis / System (CNS) disease / H5N1 influenza / chronic gout / prostate cancer / gastroesophageal reflux disease / breast cancer / multiple myeloma treatment / cancer / schizophrenia / relapsed follicular lymphoma / advanced non-squamous non-small cell lung cancer / cognitive impairment / diabetes / endometriosis / Alzheimer-type dementia / non-metastatic osteosarcoma / recurrent colorectal cancer / refractory Hodgkin lymphoma / refractory follicular lymphoma / specific disease / cross-functional disease / chronic renal disease / metastatic castration-resistant prostate cancer / Immunology/Inflammatory / Alzheimer's dementia / obesity / relapsed multiple myeloma / resistant prostate cancer / influenza / insomnia / multiple myeloma treatment Increase / peptic ulcer / Alzheimer’s disease / hypertension / Central Nervous System Diseases / disease / lymphocyte tumor / Hodgkin lymphoma / central nervous system disorders / metastatic pancreas cancer / anemia / bipolar disorder / refractory systemic anaplastic large cell lymphoma / /
MedicalTreatment
dialysis / chemotherapy / /
Organization
Drug Discovery Unit / American Society of Hematology / R&D Organization / Kyoto University / European Union / Sanford-Burnham Medical Research Institute / Ministry of Health / New Research Center / Shonan Research Center / European Medicines Agency / Florida Hospital / U.S. Food and Drug Administration / /
Takeda Pharmaceutical Company Limited[removed]Consolidated Financial Statements for Fiscal[removed]Results of Operations (1). Analysis of Operation results 1) Introduction